CRXM Taxus Cardium Pharmaceuticals Group Inc (CE)

OMB APPROVAL

OMB Number:

3235-0058

Expires:

October 31, 2018

Estimated average burden

hours per response

2.50

(Check One)    

☐   Form 10-K     ☐   Form 20-F     ☐   Form 11-K     ☒   Form 10-Q

☐   Form 10-D     ☐   Form N-SAR     ☐   Form N-CSR

For Period Ended: March 31, 2018

☐   Transition Report on Form 10-K

☐   Transition Report on Form 20-F

☐   Transition Report on Form 11-K

☐   Transition Report on Form 10-Q

☐   Transition Report on Form N-SAR

For the Transition Period Ended:

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

☒    

(a)

The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

(c)

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

(1) 

Name and telephone number of person to contact in regard to this notification

Christopher J. Reinhard

(858) 436-1000

(Name)

(Telephone Number)

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).     ☐   Yes     ☒   No

       Form 10Q for the period ending June 30, 2017; Form 10Q for the period ending September 30, 2017; Form 10K for the period ending December 31, 2017

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?     ☐   Yes     ☒   No

Date: May 16, 2018

By:

/s/ Christopher J. Reinhard

Name: Christopher J. Reinhard

Title: Principal Executive Financial and Accounting Officer